Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug [Reuters]
Puma Biotechnology Inc (PBYI)
Last puma biotechnology inc earnings: 2/20 04:07 pm
Check Earnings Report
US:NYSE Investor Relations:
pumabiotechnology.com/ir.html
Company Research
Source: Reuters
Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug | Reuters Reuters Staff 2 Min Read Jan 23 (Reuters) - Puma Biotechnology Inc said on Tuesday a European regulatory panel indicated it was unlikely to provide a positive opinion on the company’s breast cancer drug, sending its shares down 30 percent. The setback comes six months after the U.S. Food and Drug Administration approved the experimental breast cancer drug that lowers the risk of the disease returning after initial treatment. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has pointed to a negative vote on the treatment, the company said in a statement. Final drug approvals are up to the European Commission, but it generally follows the CHMP recommendation. Puma shares were down 30 percent at $64 in extended trading. Neratinib is designed to treat early-stage breast cancer in patients with the HER2 genetic mutation in which the tumor has been surgically removed,
Show less
Read more
Impact Snapshot
Event Time:
PBYI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBYI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBYI alerts
High impacting Puma Biotechnology Inc news events
Weekly update
A roundup of the hottest topics
PBYI
News
- Puma Biotechnology, Inc. (NASDAQ: PBYI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology Reports First Quarter Financial Results [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology Reports First Quarter Financial ResultsBusiness Wire
PBYI
Earnings
- 5/2/24 - Beat
PBYI
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/26/24 - Form DEFA14A
- PBYI's page on the SEC website